Skip to content

Safety and efficacy of target controlled infusion of remifentanil combined with dexmedetomidine for percutaneous foraminoscopy

Safety and efficacy of target controlled infusion of remifentanil combined with dexmedetomidine for percutaneous foraminoscopy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093668
Enrollment
Unknown
Registered
2024-12-10
Start date
2024-12-10
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar disc herniation

Interventions

Control group (Group A):After the patient was monitored, the infusion was completed within 10 minutes with 1.0ug/kg dexmedetomidine as the load dose, and 1µg/kg fentanyl was given 5 minutes before the
Experimental group (Group B):After the patient was monitored, the infusion was completed within 10 minutes at 0.8µg/kg dexmedetomidine as the load dose, and then continued at 0.4~0.6µg/kg·h. The remif

Sponsors

Surgery Center, Department of Anesthesiology, The First Affiliated Hospital of Gannan Medical University, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Select patients who meet the operative indications for percutaneous intervertebral arthroscopy and who consent to the operation; 2. American Society of Anesthesiologists grade I to II, age 18 to 60 years; 3. Patients were informed of this study and signed informed consent;

Exclusion criteria

Exclusion criteria: 1. Refuse to participate in this researcher; 2. Patients with vital organ dysfunction; 3. Patients with severe hypertension and diabetes; 4. Those allergic to dexmedetomidine and remifentanil; 5. Patients with severe bradycardia and conduction block; 6. A history of chronic pain, mental illness, alcohol or drug abuse; 7. Long-term use of sedative or analgesic drugs; 8. Myasthenia gravis or bronchial asthma; 9. body mass index (BMI)>28 or < 18kg/m2; 10. People with language and communication disabilities; 11. Pregnant or lactating patients 12. Patients entering the operating room with resting blood oxygen saturation (SpO2) <=95%

Design outcomes

Primary

MeasureTime frame
Observer's Assessment of Alertness/Sedation;Incidence of blood oxygen saturation less than 95% under 2L/min nasal catheter oxygen inhalation during operation and in the anesthesia recovery room;

Secondary

MeasureTime frame
Visual analogue scale;Anesthesia recovery time;Duration of stay in anesthesia recovery room;Blood pressure;Heart rate;Respiratory rate;Mean arterial pressure;End-expiratory carbon dioxide;Respiratory depression;bradycardia;Nausea or vomiting;hypotension;Dry mouth;Patient satisfaction 4 hours after surgery;Total dosage of dexmedetomidine;The total amount of remifentanil used;Remedy drug application;

Countries

China

Contacts

Public ContactGuoRui

First Affiliated Hospital of Gannan Medical University

haiou2018guo@163.com+86 159 0707 4021

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026